Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 4 Cases of Incomplete Artificial Ventilator Connections Reported
August 10, 2009
- R&D NEWS IN BRIEF
August 10, 2009
- Clozaril for Treatment-Resistant Schizophrenia: Novartis
August 10, 2009
- Market for Class 1 OTC Drugs Should Expand in a Few Years: Mr Tokita
August 10, 2009
- Kowas Livalo Approved in US
August 10, 2009
- Sitagliptin, Sibutramine Recommended for Approval
August 3, 2009
- Exceptional NHI Price Maintenance System Benefits Patients: Mr Nagano
August 3, 2009
- Generics, Drug Pricing Not Included in DPJ's Manifesto
August 3, 2009
- REGULATORY NEWS IN BRIEF
August 3, 2009
- Share of Generics Up 1.9 Points to 18.0% on a Volume Basis
August 3, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 3, 2009
- Kure City to Save Over ¥100 Mil. by Generics Use-Promotion Notification Service
August 3, 2009
- Bayer Schering Aims at Becoming One of World's Top-Five Oncology Companies: Mr R. Rosen
August 3, 2009
- Generic Firms Should Ally to Improve Image of Generics: Mr Kinoshita
August 3, 2009
- Chugai Keeps Top Position in Japanese Oncology Market
August 3, 2009
- Hodanren Opposed to Promotion of Use of Generics That Neglect Reality
August 3, 2009
- NBI Aims at Sales of ¥17 Bil. for Spiriva
August 3, 2009
- JLHWO to Conduct More Clinical Trials at Rosai Hospitals
August 3, 2009
- Recomodulin to Grow Big in FY2011: Asahi Kasei Pharma
August 3, 2009
- R&D NEWS IN BRIEF
August 3, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…